• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Bio Rad Laboratories (BIO) Launches New ddPCR Kits Following A Fair Value Debate

    Simply Wall St·07/12/2026 00:30:20
    Listen to the news

    Bio-Rad Laboratories (BIO) has introduced its QX700 System-compatible Vericheck ddPCR Kit portfolio, targeting quality control workflows in advanced cell and gene therapy development and broader biopharma applications, an event that may influence how investors assess the stock.

    See our latest analysis for Bio-Rad Laboratories.

    At a share price of US$296.11, Bio-Rad Laboratories has seen modest recent momentum, with a 30-day share price return of 1.75% and a 90-day gain of 6.04%. The 1-year total shareholder return of 15.23% contrasts with weaker 3 and 5 year total shareholder returns, suggesting sentiment has improved recently compared with longer term performance.

    If this kind of lab tools news has your attention, it could be a good moment to broaden your watchlist with other high potential healthcare technology opportunities through 41 healthcare AI stocks.

    Bio-Rad Laboratories now trades almost in line with one analyst price target but sits at a small premium to one intrinsic value estimate, so where does a reasonable view of fair value actually fall between those markers?

    Most Popular Narrative: 1.1% Overvalued

    The most followed narrative currently puts Bio-Rad Laboratories' fair value at $293, slightly below the last close of $296.11, which frames the stock as a touch ahead of that model.

    Resilience and stable growth in consumables and reagents, demonstrated by high single-digit growth, especially in the face of delayed academic and instrument funding, are shifting Bio-Rad's sales mix toward higher-margin, recurring revenues, supporting overall profitability and cash flow stability.

    Read the complete narrative.

    Curious what kind of revenue mix, margin lift, and future earnings multiple have to come together to justify that fair value? The narrative leans heavily on recurring consumables strength, a richer profitability profile, and a punchy earnings multiple that sits above the broader life sciences group.

    Result: Fair Value of $293 (OVERVALUED)

    Have a read of the narrative in full and understand what's behind the forecasts.

    However, softer instrument demand and pressure on Clinical Diagnostics, including policy shifts in China, could challenge the recurring consumables and margin story at Bio-Rad Laboratories that investors are watching.

    Find out about the key risks to this Bio-Rad Laboratories narrative.

    Next Steps

    If the mix of optimism and concern around Bio-Rad Laboratories feels finely balanced, it could be worth reviewing the data yourself soon and weighing both sides through 2 key rewards and 1 important warning sign

    Looking for more ideas beyond Bio-Rad Laboratories?

    If Bio-Rad Laboratories is on your radar, do not stop there; widen your opportunity set and compare it with other stocks that fit different goals and risk levels.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.